FDA, IOM Point to Need to Ramp Up Development of Abuse-Resistant and Novel Nonopioid Pain Meds

Addressing Leerink Swann’s Global Healthcare Conference last month, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, included development of abuse-resistant opioids and novel nonopioid pain therapies among the agency’s priorities this year. Woodcock spoke eight months after the Institute of Medicine issued a “blueprint for action,” calling for increased coordination of government, business, and academic efforts to improve pain prevention, care, education, and research by 2015.
Genetic Engineering & Biotechnology News